JP2010501162A - 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子 - Google Patents

肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子 Download PDF

Info

Publication number
JP2010501162A
JP2010501162A JP2009524367A JP2009524367A JP2010501162A JP 2010501162 A JP2010501162 A JP 2010501162A JP 2009524367 A JP2009524367 A JP 2009524367A JP 2009524367 A JP2009524367 A JP 2009524367A JP 2010501162 A JP2010501162 A JP 2010501162A
Authority
JP
Japan
Prior art keywords
imp
gene
lung cancer
protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009524367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501162A5 (enExample
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2010501162A publication Critical patent/JP2010501162A/ja
Publication of JP2010501162A5 publication Critical patent/JP2010501162A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009524367A 2006-08-18 2007-08-16 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子 Pending JP2010501162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83875006P 2006-08-18 2006-08-18
PCT/JP2007/066324 WO2008020652A1 (en) 2006-08-18 2007-08-16 Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer

Publications (2)

Publication Number Publication Date
JP2010501162A true JP2010501162A (ja) 2010-01-21
JP2010501162A5 JP2010501162A5 (enExample) 2010-10-07

Family

ID=38621240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524367A Pending JP2010501162A (ja) 2006-08-18 2007-08-16 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子

Country Status (4)

Country Link
US (1) US20110070245A1 (enExample)
EP (1) EP2059610A1 (enExample)
JP (1) JP2010501162A (enExample)
WO (1) WO2008020652A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936502B1 (ko) * 2016-05-30 2019-01-09 가톨릭대학교 산학협력단 간암의 진단 및 예후 예측용 바이오 마커 및 그의 용도
CN111154891B (zh) * 2020-02-10 2023-07-25 天津奥群牧业有限公司 绵羊igf2bp1基因插入/缺失多态性的检测引物对、试剂盒、方法和应用
WO2025125557A1 (en) * 2023-12-15 2025-06-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Composition comprising an antibody which binds to human igf2bp1 present on the cell surface of a target cell

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090603A2 (en) * 2004-03-23 2005-09-29 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2006038212A2 (en) * 2004-10-04 2006-04-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for the diagnosis and treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090603A2 (en) * 2004-03-23 2005-09-29 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012038635; Ｃａｎｃｅｒ　Ｌｅｔｔ．，　２００４，　２０９（２），　ｐｐ．２４５-２５０ *
JPN6012038637; ＰＮＡＳ，　２００１，　９８（２４），　ｐｐ．１３７９０-１３７９５ *
JPN6012038639; ＰＮＡＳ，　２００１，　９８（２４），　ｐｐ．１３７８４-１３７８９ *
JPN6012038640; Ｃａｎｃｅｒ　Ｒｅｓ．，　２００２，　６２（１１），　ｐｐ．３００５-３００８ *
JPN6012038642; Ｏｎｃｏｇｅｎｅ．，　２００５，　２４（４７），　ｐｐ．７１０５-７１１３ *
JPN6012038643; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　２００４，　２７９（４７），　ｐｐ．４８７１６-４８７２４ *

Also Published As

Publication number Publication date
EP2059610A1 (en) 2009-05-20
WO2008020652A1 (en) 2008-02-21
US20110070245A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
US20110301056A1 (en) Nectin-4 for target genes of cancer therapy and diagnosis
JP2010536366A (ja) 肺癌の治療及び診断の標的遺伝子のためのｅｂｉ３、ｄｌｘ５、ｎｐｔｘ１、及びｃｄｋｎ３
EP2468887A1 (en) TTK as tumor marker and therapeutic target for lung cancer
WO2007013575A2 (en) Method for diagnosing and treating renal cell carcinoma
JP2010523081A (ja) Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子
WO2012090479A1 (en) Mcm7 as a target gene for cancer therapy and diagnosis
US20110262463A1 (en) Syngr4 for target genes of cancer therapy and diagnosis
JP2012501163A (ja) がんの治療および診断用の標的遺伝子としてのｃ１２ｏｒｆ４８
WO2009113295A1 (en) C2orf18 as target gene for cancer therapy and diagnosis
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
JP2012501162A (ja) 癌の治療および診断のための標的遺伝子としてのｏｉｐ５
WO2010023854A1 (en) Cancer related gene, lgn/gpsm2
WO2012153492A1 (en) Nptx2 as tumor marker and therapeutic target for cancer
JP2013502901A (ja) がんの治療および診断の標的遺伝子としてのｅｒｃｃ６ｌ
JP2010500004A (ja) 前立腺癌関連遺伝子ｓｔｙｋ１
JP2009505631A (ja) 癌関連遺伝子ｒａｓｇｅｆ１ａ
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
WO2011021386A1 (en) Cstf2 for target genes of lung cancer therapy and diagnosis
WO2011018898A1 (en) Cdc45l as tumor marker and therapeutic target for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130410